CL2016001120A1 - Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct - Google Patents
Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pctInfo
- Publication number
- CL2016001120A1 CL2016001120A1 CL2016001120A CL2016001120A CL2016001120A1 CL 2016001120 A1 CL2016001120 A1 CL 2016001120A1 CL 2016001120 A CL2016001120 A CL 2016001120A CL 2016001120 A CL2016001120 A CL 2016001120A CL 2016001120 A1 CL2016001120 A1 CL 2016001120A1
- Authority
- CL
- Chile
- Prior art keywords
- compounds
- treatment
- pharmaceutical composition
- pyrrolo1
- 4triazine
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 4
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 230000009385 viral infection Effects 0.000 title 1
- 241000700605 Viruses Species 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H7/00—Compounds containing non-saccharide radicals linked to saccharide radicals by a carbon-to-carbon bond
- C07H7/06—Heterocyclic radicals
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Molecular Biology (AREA)
- Virology (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Engineering & Computer Science (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Saccharide Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
LA SOLICITUD SE REFIERE A COMPUESTOS DERIVADOS DE PIRROLO1,2-F1,2,4TRIAZINA , A UNA COMPOSICIÓN FARMACÉUTICA QUE LOS COMPRENDE Y A SU USO EN EL TRATAMIENTO DE UNA INFECCIÓN POR VIRUS SINCICIAL COMPUESTOS INTERMEDIARIOS.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361902544P | 2013-11-11 | 2013-11-11 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CL2016001120A1 true CL2016001120A1 (es) | 2017-05-05 |
Family
ID=52003049
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CL2016001120A CL2016001120A1 (es) | 2013-11-11 | 2016-05-11 | Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct |
Country Status (36)
| Country | Link |
|---|---|
| US (5) | US9388208B2 (es) |
| EP (3) | EP3068405B1 (es) |
| JP (7) | JP6234571B2 (es) |
| KR (4) | KR102113705B1 (es) |
| CN (3) | CN114085243B (es) |
| AP (1) | AP2016009186A0 (es) |
| AU (5) | AU2014346665A1 (es) |
| BR (1) | BR112016010261B1 (es) |
| CA (1) | CA2928674C (es) |
| CL (1) | CL2016001120A1 (es) |
| CR (1) | CR20160220A (es) |
| CU (1) | CU20160065A7 (es) |
| CY (1) | CY1121948T1 (es) |
| DK (2) | DK3068405T3 (es) |
| DO (1) | DOP2016000107A (es) |
| EA (2) | EA029712B1 (es) |
| ES (2) | ES2743619T3 (es) |
| GT (1) | GT201600086A (es) |
| HR (2) | HRP20220920T1 (es) |
| HU (2) | HUE044960T2 (es) |
| IL (1) | IL245324B (es) |
| LT (2) | LT3505173T (es) |
| MD (1) | MD4596C1 (es) |
| MX (2) | MX376186B (es) |
| MY (2) | MY197933A (es) |
| NZ (1) | NZ719592A (es) |
| PE (1) | PE20160670A1 (es) |
| PH (1) | PH12016500867A1 (es) |
| PL (2) | PL3068405T3 (es) |
| PT (2) | PT3068405T (es) |
| SG (1) | SG11201603427XA (es) |
| SI (2) | SI3068405T1 (es) |
| TR (1) | TR201910961T4 (es) |
| UA (1) | UA119050C2 (es) |
| WO (1) | WO2015069939A1 (es) |
| ZA (1) | ZA201603123B (es) |
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11773126B2 (en) | 2017-09-18 | 2023-10-03 | Janssen Pharmaceuticals, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
Families Citing this family (53)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HRP20130862T1 (hr) | 2009-09-21 | 2013-10-25 | Gilead Sciences, Inc. | Procesi i intermedijeri za pripravu analoga 1'-cijanokarbanukleozida |
| UA111163C2 (uk) | 2010-07-22 | 2016-04-11 | Гайлід Сайєнсіз, Інк. | Способи й сполуки для лікування вірусних інфекцій paramyxoviridae |
| UA119050C2 (uk) * | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ |
| WO2015143712A1 (en) | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
| TWI678369B (zh) * | 2014-07-28 | 2019-12-01 | 美商基利科學股份有限公司 | 用於治療呼吸道合胞病毒感染之噻吩並［３,２-ｄ］嘧啶、呋喃並［３,２-ｄ］嘧啶及吡咯並［３,２-ｄ］嘧啶化合物類 |
| EP3197457B1 (en) | 2014-09-26 | 2022-11-09 | Riboscience LLC | 4'-vinyl substituted nucleoside derivatives as inhibitors of respiratory syncytial virus rna replication |
| TWI767201B (zh) | 2014-10-29 | 2022-06-11 | 美商基利科學股份有限公司 | 絲狀病毒科病毒感染之治療 |
| SG11201705069YA (en) | 2014-12-26 | 2017-07-28 | Univ Emory | N4-hydroxycytidine and derivatives and anti-viral uses related thereto |
| MA52371A (fr) | 2015-09-16 | 2021-09-22 | Gilead Sciences Inc | Méthodes de traitement d'infections dues aux coronaviridae |
| WO2017053216A2 (en) * | 2015-09-23 | 2017-03-30 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors and preparations thereof |
| CN109071467B (zh) | 2016-03-09 | 2023-04-04 | 艾丽奥斯生物制药有限公司 | 无环抗病毒药 |
| CA3056072C (en) | 2017-03-14 | 2022-08-23 | Gilead Sciences, Inc. | Methods of treating feline coronavirus infections |
| JP2020518578A (ja) | 2017-05-01 | 2020-06-25 | ギリアード サイエンシーズ， インコーポレイテッド | （Ｓ）−２−エチルブチル２−（（（Ｓ）−（（（２Ｒ，３Ｓ，４Ｒ，５Ｒ）−５−（４−アミノピロロ［２，１−ｆ］［１，２，４］トリアジン−７−イル）−５−シアノ−３，４−ジヒドロキシテトラヒドロフラン−２−イル）メトキシ）（フェノキシ）ホスホリル）アミノ）プロパノエートの結晶形態 |
| ES3000461T3 (en) | 2017-07-11 | 2025-02-28 | Gilead Sciences Inc | Compositions comprising an rna polymerase inhibitor and cyclodextrin for treating viral infections |
| CN109748921B (zh) * | 2017-11-03 | 2022-03-22 | 中国科学院上海药物研究所 | N-叔丁氧羰基保护的杂环类化合物、其制备方法及其用于制备c-核苷类似物的方法 |
| PL3706762T3 (pl) | 2017-12-07 | 2025-02-10 | Emory University | N4-hydroksycytydyna i pochodne oraz związane z nimi zastosowania przeciwwirusowe |
| US11040975B2 (en) | 2017-12-08 | 2021-06-22 | Merck Sharp & Dohme Corp. | Carbocyclic nucleoside reverse transcriptase inhibitors |
| CN108787177B (zh) * | 2018-08-07 | 2024-03-15 | 中南大学 | 淤浆法制备黄原酸盐的方法及系统 |
| US12234255B2 (en) | 2019-05-14 | 2025-02-25 | Regents Of The University Of Michigan | Methods for glycosylation |
| JP2023512656A (ja) | 2020-01-27 | 2023-03-28 | ギリアード サイエンシーズ， インコーポレイテッド | ＳＡＲＳ ＣｏＶ－２感染を治療するための方法 |
| AR121356A1 (es) * | 2020-02-18 | 2022-05-11 | Gilead Sciences Inc | Compuestos antivirales |
| TWI794742B (zh) * | 2020-02-18 | 2023-03-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI775313B (zh) | 2020-02-18 | 2022-08-21 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| TWI791193B (zh) * | 2020-02-18 | 2023-02-01 | 美商基利科學股份有限公司 | 抗病毒化合物 |
| CN111187269A (zh) * | 2020-02-27 | 2020-05-22 | 江苏阿尔法药业有限公司 | 一种瑞德西韦中间体的合成方法 |
| CN113336758B (zh) * | 2020-03-03 | 2022-08-19 | 北京桦冠医药科技有限公司 | 化合物7-碘吡咯并[2，1-f][1，2，4]三嗪-4-胺的一种新合成方法 |
| CN111233870A (zh) * | 2020-03-11 | 2020-06-05 | 中国科学技术大学 | 用于快速制备瑞德西韦药物中间体的方法 |
| TWI890963B (zh) | 2020-03-12 | 2025-07-21 | 美商基利科學股份有限公司 | 1'-氰基核苷之製備方法 |
| AU2021251689B2 (en) | 2020-04-06 | 2024-06-13 | Gilead Sciences, Inc. | Inhalation formulations of 1'-cyano substituted carbanucleoside analogs |
| CN112778310B (zh) | 2020-04-20 | 2025-05-30 | 中国科学院上海药物研究所 | 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用 |
| CN113527303B (zh) * | 2020-04-21 | 2022-06-10 | 浙江工业大学 | 一种瑞德西韦母核中间体的制备工艺 |
| CN111440176B (zh) * | 2020-04-28 | 2022-04-26 | 江苏大学 | 金属配合物促进的瑞德西韦中间体的合成方法 |
| TW202532084A (zh) | 2020-05-29 | 2025-08-16 | 美商基利科學股份有限公司 | 瑞德西韋之治療方法 |
| CN111620903A (zh) * | 2020-06-17 | 2020-09-04 | 安徽贝克联合制药有限公司 | C-核苷类似物以及用于合成瑞德西韦合成的含腈c-核苷类化合物的制备方法及其应用 |
| IL299202A (en) | 2020-06-24 | 2023-02-01 | Gilead Sciences Inc | 1'-cyano nucleoside analogs and uses thereof |
| CN111732618A (zh) * | 2020-07-03 | 2020-10-02 | 镇江巨杰新材料技术研发中心(有限合伙) | 瑞德西韦关键片段的合成方法 |
| CN111793101B (zh) * | 2020-07-17 | 2022-09-30 | 四川大学 | C-核苷化合物的合成方法 |
| CA3185450A1 (en) | 2020-08-06 | 2022-02-10 | Istvan Borza | Remdesivir intermediates |
| US11773122B2 (en) | 2020-08-24 | 2023-10-03 | Gilead Sciences. Inc. | Phospholipid compounds and uses thereof |
| PE20231983A1 (es) | 2020-08-27 | 2023-12-12 | Gilead Sciences Inc | Compuestos y metodos para el tratamiento de infecciones virales |
| TWI811812B (zh) * | 2020-10-16 | 2023-08-11 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| CN113880846B (zh) * | 2020-12-31 | 2022-10-14 | 山东诚汇双达药业有限公司 | 一种7-碘吡咯并[2,1-f][1,2,4]三嗪-4-胺的制备方法 |
| ES3028915T3 (en) | 2021-04-16 | 2025-06-20 | Gilead Sciences Inc | Methods of preparing carbanucleosides using amides |
| EP4387977A1 (en) | 2021-08-18 | 2024-06-26 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| PE20240654A1 (es) | 2021-08-20 | 2024-04-04 | Shionogi & Co | Derivados de nucleosido y profarmacos de los mismos que tienen accion inhibidora del crecimiento viral |
| CA3244278A1 (en) | 2022-03-02 | 2023-09-07 | Gilead Sciences Inc | COMPOUNDS AND METHODS FOR THE TREATMENT OF VIRAL INFECTIONS |
| US20230382940A1 (en) | 2022-03-03 | 2023-11-30 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
| CA3252494A1 (en) * | 2022-03-03 | 2023-09-07 | Gilead Sciences Inc | ANTIVIRAL COMPOUNDS AND THEIR MANUFACTURING AND USAGE PROCESSES |
| US20240309028A1 (en) | 2023-02-16 | 2024-09-19 | Gilead Sciences, Inc. | Phospholipid compounds and methods of making and using the same |
| US20250084088A1 (en) | 2023-08-31 | 2025-03-13 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
| WO2025049699A1 (en) | 2023-08-31 | 2025-03-06 | Gilead Sciences, Inc. | Antiviral compounds and methods of making and using the same |
| TW202517647A (zh) | 2023-09-28 | 2025-05-01 | 美商基利科學股份有限公司 | 用於治療病毒感染的化合物及方法 |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
Family Cites Families (44)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3361306A (en) | 1966-03-31 | 1968-01-02 | Merck & Co Inc | Aerosol unit dispensing uniform amounts of a medically active ingredient |
| US3565070A (en) | 1969-02-28 | 1971-02-23 | Riker Laboratories Inc | Inhalation actuable aerosol dispenser |
| FR2224175B1 (es) | 1973-04-04 | 1978-04-14 | Isf Spa | |
| US4069819A (en) | 1973-04-13 | 1978-01-24 | Societa Farmaceutici S.P.A. | Inhalation device |
| IT1017153B (it) | 1974-07-15 | 1977-07-20 | Isf Spa | Apparecchio per inalazioni |
| SE438261B (sv) | 1981-07-08 | 1985-04-15 | Draco Ab | Anvendning i dosinhalator av ett perforerat membran |
| US4805811A (en) | 1985-03-29 | 1989-02-21 | Aktiebolaget Draco | Dosage device |
| SE448277B (sv) | 1985-04-12 | 1987-02-09 | Draco Ab | Indikeringsanordning vid en doseringsanordning for lekemedel |
| IT1228459B (it) | 1989-02-23 | 1991-06-19 | Phidea S R L | Inalatore con svuotamento regolare e completo della capsula. |
| US4955371A (en) | 1989-05-08 | 1990-09-11 | Transtech Scientific, Inc. | Disposable inhalation activated, aerosol device for pulmonary medicine |
| CA2112674C (en) | 1991-07-02 | 2005-10-04 | John S. Patton | Method and device for delivering aerosolized medicaments |
| US5261538A (en) | 1992-04-21 | 1993-11-16 | Glaxo Inc. | Aerosol testing method |
| US5785049A (en) | 1994-09-21 | 1998-07-28 | Inhale Therapeutic Systems | Method and apparatus for dispersion of dry powder medicaments |
| US5388572A (en) | 1993-10-26 | 1995-02-14 | Tenax Corporation (A Connecticut Corp.) | Dry powder medicament inhalator having an inhalation-activated piston to aerosolize dose and deliver same |
| US5522385A (en) | 1994-09-27 | 1996-06-04 | Aradigm Corporation | Dynamic particle size control for aerosolized drug delivery |
| US5544647A (en) | 1994-11-29 | 1996-08-13 | Iep Group, Inc. | Metered dose inhalator |
| US5622163A (en) | 1994-11-29 | 1997-04-22 | Iep Group, Inc. | Counter for fluid dispensers |
| US6116234A (en) | 1999-02-01 | 2000-09-12 | Iep Pharmaceutical Devices Inc. | Metered dose inhaler agitator |
| KR101005299B1 (ko) * | 2000-10-18 | 2011-01-04 | 파마셋 인코포레이티드 | 바이러스 감염 및 비정상적인 세포 증식의 치료를 위한 변형된 뉴클레오시드 |
| GB0114286D0 (en) | 2001-06-12 | 2001-08-01 | Hoffmann La Roche | Nucleoside Derivatives |
| WO2003026589A2 (en) | 2001-09-28 | 2003-04-03 | Idenix (Cayman) Limited | Methods and compositions for treating hepatitis c virus using 4'-modified nucleosides |
| WO2005020885A2 (en) | 2003-05-21 | 2005-03-10 | Isis Pharmaceuticals, Inc. | Compositions and methods for the treatment of severe acute respiratory syndrome (sars) |
| AR046959A1 (es) * | 2003-12-18 | 2006-01-04 | Tibotec Pharm Ltd | Morfolinilo que contiene bencimidazoles como inhibidores de la replicacion del virus sincitial respiratorio |
| SG177974A1 (en) * | 2007-01-12 | 2012-02-28 | Biocryst Pharm Inc | Antiviral nucleoside analogs |
| CA2685520A1 (en) | 2007-05-10 | 2008-11-20 | Biocryst Pharmaceuticals, Inc. | Tetrahydrofuro [3 4-d] dioxolane compounds for use in the treatment of viral infections and cancer |
| EP2019519B1 (en) | 2007-07-25 | 2011-07-06 | Nokia Siemens Networks Oy | Method for addressing ethernet streams with a structured GPON GEM Port ID |
| AR071395A1 (es) * | 2008-04-23 | 2010-06-16 | Gilead Sciences Inc | Analogos carba-nucleosidos 1'-sustituidos para tratamiento antiviral |
| EP2313102A2 (en) | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
| US8455451B2 (en) | 2009-09-21 | 2013-06-04 | Gilead Sciences, Inc. | 2'-fluoro substituted carba-nucleoside analogs for antiviral treatment |
| ES2730805T3 (es) | 2009-09-21 | 2019-11-12 | Gilead Sciences Inc | Análogos de carba-nucleósido sustituido por 2'-fluoro para el tratamiento antiviral |
| HRP20130862T1 (hr) | 2009-09-21 | 2013-10-25 | Gilead Sciences, Inc. | Procesi i intermedijeri za pripravu analoga 1'-cijanokarbanukleozida |
| TW201201815A (en) | 2010-05-28 | 2012-01-16 | Gilead Sciences Inc | 1'-substituted-carba-nucleoside prodrugs for antiviral treatment |
| NZ606141A (en) | 2010-07-19 | 2015-03-27 | Gilead Sciences Inc | Methods for the preparation of diasteromerically pure phosphoramidate prodrugs |
| UA111163C2 (uk) * | 2010-07-22 | 2016-04-11 | Гайлід Сайєнсіз, Інк. | Способи й сполуки для лікування вірусних інфекцій paramyxoviridae |
| TW201305185A (zh) | 2010-09-13 | 2013-02-01 | Gilead Sciences Inc | 用於抗病毒治療之２’－氟取代之碳－核苷類似物 |
| WO2012039791A1 (en) * | 2010-09-20 | 2012-03-29 | Gilead Sciences, Inc. | 2' -fluoro substituted carba-nucleoside analogs for antiviral treatment |
| CA2822037A1 (en) * | 2010-12-20 | 2012-06-28 | Gilead Sciences, Inc. | Methods for treating hcv |
| WO2012142075A1 (en) | 2011-04-13 | 2012-10-18 | Merck Sharp & Dohme Corp. | 2'-azido substituted nucleoside derivatives and methods of use thereof for the treatment of viral diseases |
| US20130143835A1 (en) * | 2011-12-05 | 2013-06-06 | Medivir Ab | HCV Polymerase Inhibitors |
| AU2012358803C1 (en) * | 2011-12-22 | 2019-12-19 | Janssen Biopharma, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
| WO2013138236A1 (en) * | 2012-03-13 | 2013-09-19 | Gilead Sciences , Inc. | 2'- substituted carba-nucleoside analogs for antiviral treatment |
| CN104936970A (zh) | 2012-10-08 | 2015-09-23 | 埃迪尼克斯医药公司 | 用于hcv感染的2′-氯核苷类似物 |
| TWI582077B (zh) | 2013-11-07 | 2017-05-11 | 必治妥美雅史谷比公司 | 作爲ＩＬ－１２、ＩＬ－２３及／或ＩＦＮα反應調節劑之經烷基－醯胺取代之吡啶化合物 |
| UA119050C2 (uk) | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ |
-
2014
- 2014-06-11 UA UAA201606308A patent/UA119050C2/uk unknown
- 2014-11-06 US US14/534,715 patent/US9388208B2/en active Active
- 2014-11-06 PT PT14806123T patent/PT3068405T/pt unknown
- 2014-11-06 SI SI201431284T patent/SI3068405T1/sl unknown
- 2014-11-06 ES ES14806123T patent/ES2743619T3/es active Active
- 2014-11-06 KR KR1020187014999A patent/KR102113705B1/ko active Active
- 2014-11-06 CN CN202111444706.3A patent/CN114085243B/zh active Active
- 2014-11-06 KR KR1020167015220A patent/KR101864973B1/ko active Active
- 2014-11-06 KR KR1020217011476A patent/KR102355881B1/ko active Active
- 2014-11-06 MD MDA20160063A patent/MD4596C1/ro not_active IP Right Cessation
- 2014-11-06 JP JP2016528882A patent/JP6234571B2/ja active Active
- 2014-11-06 AU AU2014346665A patent/AU2014346665A1/en not_active Abandoned
- 2014-11-06 PT PT182092676T patent/PT3505173T/pt unknown
- 2014-11-06 PL PL14806123T patent/PL3068405T3/pl unknown
- 2014-11-06 PL PL18209267.6T patent/PL3505173T3/pl unknown
- 2014-11-06 CA CA2928674A patent/CA2928674C/en active Active
- 2014-11-06 EP EP14806123.7A patent/EP3068405B1/en active Active
- 2014-11-06 ES ES18209267T patent/ES2926155T3/es active Active
- 2014-11-06 NZ NZ719592A patent/NZ719592A/en unknown
- 2014-11-06 MY MYPI2021000404A patent/MY197933A/en unknown
- 2014-11-06 BR BR112016010261-4A patent/BR112016010261B1/pt active IP Right Grant
- 2014-11-06 EA EA201690978A patent/EA029712B1/ru unknown
- 2014-11-06 HU HUE14806123A patent/HUE044960T2/hu unknown
- 2014-11-06 CN CN201910045494.8A patent/CN110003215B/zh active Active
- 2014-11-06 MX MX2016006066A patent/MX376186B/es active IP Right Grant
- 2014-11-06 DK DK14806123.7T patent/DK3068405T3/da active
- 2014-11-06 TR TR2019/10961T patent/TR201910961T4/tr unknown
- 2014-11-06 EA EA201792639A patent/EA039734B1/ru unknown
- 2014-11-06 SG SG11201603427XA patent/SG11201603427XA/en unknown
- 2014-11-06 AP AP2016009186A patent/AP2016009186A0/en unknown
- 2014-11-06 WO PCT/US2014/064412 patent/WO2015069939A1/en not_active Ceased
- 2014-11-06 HR HRP20220920TT patent/HRP20220920T1/hr unknown
- 2014-11-06 MY MYPI2016701599A patent/MY182986A/en unknown
- 2014-11-06 EP EP22182880.9A patent/EP4122932A1/en active Pending
- 2014-11-06 CN CN201480072871.2A patent/CN105899216B/zh active Active
- 2014-11-06 HR HRP20191303TT patent/HRP20191303T1/hr unknown
- 2014-11-06 SI SI201431978T patent/SI3505173T1/sl unknown
- 2014-11-06 DK DK18209267.6T patent/DK3505173T3/da active
- 2014-11-06 KR KR1020207013948A patent/KR102243724B1/ko active Active
- 2014-11-06 EP EP18209267.6A patent/EP3505173B1/en active Active
- 2014-11-06 LT LTEP18209267.6T patent/LT3505173T/lt unknown
- 2014-11-06 PE PE2016000605A patent/PE20160670A1/es unknown
- 2014-11-06 LT LTEP14806123.7T patent/LT3068405T/lt unknown
- 2014-11-06 HU HUE18209267A patent/HUE059683T2/hu unknown
-
2016
- 2016-04-27 IL IL245324A patent/IL245324B/en active IP Right Grant
- 2016-05-09 DO DO2016000107A patent/DOP2016000107A/es unknown
- 2016-05-09 MX MX2020010628A patent/MX2020010628A/es unknown
- 2016-05-10 ZA ZA2016/03123A patent/ZA201603123B/en unknown
- 2016-05-10 PH PH12016500867A patent/PH12016500867A1/en unknown
- 2016-05-11 CR CR20160220A patent/CR20160220A/es unknown
- 2016-05-11 CL CL2016001120A patent/CL2016001120A1/es unknown
- 2016-05-11 GT GT201600086A patent/GT201600086A/es unknown
- 2016-05-11 CU CUP2016000065A patent/CU20160065A7/es unknown
- 2016-06-14 US US15/182,529 patent/US9701682B2/en active Active
-
2017
- 2017-05-31 US US15/610,104 patent/US10059716B2/en active Active
- 2017-08-23 JP JP2017160336A patent/JP6393380B2/ja active Active
- 2017-09-18 AU AU2017232039A patent/AU2017232039C1/en active Active
-
2018
- 2018-01-05 JP JP2018000710A patent/JP2018070658A/ja not_active Withdrawn
- 2018-07-25 US US16/045,371 patent/US10377761B2/en active Active
-
2019
- 2019-06-21 AU AU2019204381A patent/AU2019204381B2/en active Active
- 2019-07-30 CY CY20191100814T patent/CY1121948T1/el unknown
- 2019-12-09 JP JP2019222179A patent/JP7054394B2/ja active Active
-
2020
- 2020-11-20 JP JP2020193294A patent/JP7247155B2/ja active Active
-
2021
- 2021-03-11 AU AU2021201554A patent/AU2021201554B2/en active Active
-
2022
- 2022-04-07 JP JP2022063956A patent/JP2022088661A/ja not_active Withdrawn
-
2023
- 2023-04-26 AU AU2023202506A patent/AU2023202506B2/en active Active
-
2024
- 2024-01-19 JP JP2024006714A patent/JP2024041986A/ja not_active Withdrawn
- 2024-08-30 US US18/821,476 patent/US20250236623A1/en active Pending
Cited By (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US11773126B2 (en) | 2017-09-18 | 2023-10-03 | Janssen Pharmaceuticals, Inc. | Substituted nucleosides, nucleotides and analogs thereof |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2016001120A1 (es) | Compuestos derivados de pirrolo1,2-f1,2,4triazina ,composición farmacéutica que los comprende y su uso en el tratamiento de una infección por virus sincicial compuestos intermediarios. pct | |
| CL2023001910A1 (es) | Derivado de glucagón y una composición que comprende un conjugado de acción prolongada del mismo | |
| CL2016000381A1 (es) | Compuestos antivirales | |
| CL2015003615A1 (es) | Nucleósidos sustituidos, nucleótidos y análogos de los mismos. | |
| CL2016001933A1 (es) | Compuestos derivados de macrociclos, inhibidores del factor xia composición farmacéutica que los comprende y su uso en el tratamiento yo profilaxis de una enfermedad tromboembolica. pct | |
| CL2014002093A1 (es) | Compuestos derivados piperidinopirimidinicos; composicion farmaceutica que los comprende; uso en el tratamiento de infecciones viricas. | |
| MX2016003199A (es) | Compuestos de azapiridona y usos de los mismos. | |
| UY35300A (es) | Formulación de combinación de dos compuestos antivirales | |
| CL2015003298A1 (es) | Novedosas heteroarildihidropirimidinas unidas por puentes en 6 para el tratamiento y la profilaxis de infeccion por el virus de la hepatitis b | |
| CL2016002414A1 (es) | Compuestos derivados de nucleosidos, inhibidores de la transcriptasa inversas composición farmacéutica que los comprende y su uso en el tratamiento de una infección por vih. pct | |
| BR112017002370A2 (pt) | indóis para uso na infecção pelo vírus da gripe | |
| CL2015000295A1 (es) | Compuestos derivados de alquilpirimidina; composicion farmaceutica que los comprende; uso para el tratamiento de infecciones víricas y otras enfermedades. | |
| GT201400144A (es) | Nuevos derivados de pirrol, su procedimiento de preparación y las composiciones farmacéuticas que los contienen | |
| CL2016000493A1 (es) | Inhibidores de polimerasa hcv. | |
| CL2016000153A1 (es) | Derivados de pirrolamida sustituidos con glioxamida y su uso como medicamentos para el tratamiento de la hepatitis b | |
| CL2015001864A1 (es) | Compuestos derivados de espiropirido[1,2-a]pirazina sustituidos, como inhibidores de la integrasa del vih; composicion farmaceutica que los comprende; y su uso para la profilaxis o el tratamiento de una infeccion por vih. | |
| CL2015002164A1 (es) | Formulación combinada de dos compuesos antivirales. | |
| CL2015003569A1 (es) | “compuestos derivados de (aril ó heteroaril)metil-2-(aril, heterociclil, cicloalquil ó alquil)-1,3-dioxan-metoxi-fenil-piperazin-1-il-fenil-heterociclil sustituido; composición farmacéutica que los comprende; su uso en el tratamiento de la fibrosis”. pct | |
| JOP20140114B1 (ar) | مركبات حلقية غير متجانسة واستخداماتها | |
| CL2015002891A1 (es) | Deaza-purinonas macrocíclicas para el tratamiento de infecciones virales. | |
| EA201591004A1 (ru) | Производные бороновой кислоты и их терапевтическое применение | |
| CL2016002835A1 (es) | “compuestos derivados de pladienolida con un resto piridinico; composición farmacéutica que los comprende; y su uso en el tratamiento del cáncer”. pct | |
| EA201690687A1 (ru) | Ингибиторы репликации вируса иммунодефицита | |
| CL2015003357A1 (es) | Derivados de nucleósidos 4'-fluoro-2'-metil sustituidos | |
| ECSP18061667A (es) | Pirimidinas sustituidas con arilo para su uso en la infección por virus influenza |